Rimegepant: A New CGRP-Blocking Pill for Migraine That Works Differently Than Triptans
Rimegepant is an FDA-approved CGRP receptor antagonist that offers a new mechanism for treating acute migraine, particularly for patients who can't take triptans.
Quick Facts
What This Study Found
Rimegepant is a small molecule that blocks the CGRP receptor. It was developed based on the improved understanding of migraine as a neurovascular condition involving vasoactive peptides, particularly CGRP.
It is approved for acute treatment of migraine in adults with or without aura. In clinical trials, it decreased pain and reduced symptoms associated with migraine attacks.
Rimegepant is part of a wave of new migraine treatments in the past 3 years that includes:
- Acute treatments: lasmiditan, rimegepant, ubrogepant
- Preventive treatments: erenumab, fremanezumab, galcanezumab, eptinezumab
All of these target the neurovascular migraine pathway, with CGRP being the central peptide involved.
Key Numbers
Rimegepant 75 mg oral; FDA-approved for acute and preventive migraine; CGRP receptor antagonist
How They Did This
This is a narrative review covering the pharmacology, clinical evidence, and place in therapy of rimegepant for acute migraine treatment.
Why This Research Matters
Most acute migraine treatments have been triptans, which do not work for everyone and are contraindicated in some patients with cardiovascular disease. CGRP receptor antagonists like rimegepant offer a new mechanism with a different safety profile, expanding options for migraine sufferers.
The Bigger Picture
The discovery that CGRP drives migraine pathophysiology led to an entire new drug class — both small molecule antagonists (gepants like rimegepant) and monoclonal antibodies (like erenumab). This represents the first time migraine drugs were designed based on understanding the disease mechanism rather than discovered by chance. Rimegepant's dual approval for both acute and preventive use makes it uniquely versatile.
What This Study Doesn't Tell Us
This is a brief review without new clinical data. It does not deeply compare rimegepant to ubrogepant or triptans. Long-term safety data are still accumulating. Cost and insurance coverage remain barriers for many patients.
Questions This Raises
- ?How does rimegepant compare to ubrogepant and newer gepants in head-to-head studies?
- ?Is long-term daily rimegepant for prevention as safe as every-other-day dosing?
- ?Could CGRP-pathway drugs eventually replace triptans as first-line migraine treatment?
Trust & Context
- Key Stat:
- 7 new CGRP drugs Rimegepant is part of a wave of seven new migraine treatments targeting the CGRP pathway released within three years
- Evidence Grade:
- This review summarizes FDA-approved clinical evidence from phase 3 trials. While the review itself is narrative, rimegepant's approval was based on rigorous randomized controlled trials demonstrating efficacy and safety.
- Study Age:
- Published in 2021, this review captures rimegepant near its initial approval. Since then, additional evidence for preventive use and long-term safety has accumulated, further establishing the drug's clinical role.
- Original Title:
- Rimegepant: acute treatment for migraine headaches.
- Published In:
- Pain management, 11(3), 259-266 (2021)
- Authors:
- Peters, Golden L, Hennessey, Erin K
- Database ID:
- RPEP-05682
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is CGRP and why does blocking it help migraines?
CGRP (calcitonin gene-related peptide) is a molecule released during migraine attacks that dilates blood vessels and transmits pain signals in the brain. Blocking CGRP or its receptor can stop these processes, relieving migraine pain and associated symptoms like nausea and light sensitivity.
How is rimegepant different from triptans?
Triptans constrict blood vessels, which is why they can't be used by people with heart disease. Rimegepant works by blocking the CGRP receptor without constricting blood vessels, giving it a different safety profile. It can also be used for both treating and preventing migraines, unlike most triptans.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05682APA
Peters, Golden L; Hennessey, Erin K. (2021). Rimegepant: acute treatment for migraine headaches.. Pain management, 11(3), 259-266. https://doi.org/10.2217/pmt-2020-0090
MLA
Peters, Golden L, et al. "Rimegepant: acute treatment for migraine headaches.." Pain management, 2021. https://doi.org/10.2217/pmt-2020-0090
RethinkPeptides
RethinkPeptides Research Database. "Rimegepant: acute treatment for migraine headaches." RPEP-05682. Retrieved from https://rethinkpeptides.com/research/peters-2021-rimegepant-acute-treatment-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.